CN106413706A - 三麦芽酚铁的剂量方案 - Google Patents

三麦芽酚铁的剂量方案 Download PDF

Info

Publication number
CN106413706A
CN106413706A CN201580005412.7A CN201580005412A CN106413706A CN 106413706 A CN106413706 A CN 106413706A CN 201580005412 A CN201580005412 A CN 201580005412A CN 106413706 A CN106413706 A CN 106413706A
Authority
CN
China
Prior art keywords
iron
formulation
anemia
use according
iron deficiency
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580005412.7A
Other languages
English (en)
Chinese (zh)
Inventor
克里斯蒂安·施魏格尔
卡尔·安德鲁·斯特瑞特
朱利安·大卫·豪厄尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
British Aegis Tx Co ltd
Original Assignee
Iron Therapeutics Holdings AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201400171A external-priority patent/GB201400171D0/en
Priority claimed from GB201418708A external-priority patent/GB201418708D0/en
Application filed by Iron Therapeutics Holdings AG filed Critical Iron Therapeutics Holdings AG
Priority to CN202111268204.XA priority Critical patent/CN114010629A/zh
Publication of CN106413706A publication Critical patent/CN106413706A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201580005412.7A 2014-01-06 2015-01-06 三麦芽酚铁的剂量方案 Pending CN106413706A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111268204.XA CN114010629A (zh) 2014-01-06 2015-01-06 三麦芽酚铁的剂量方案

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1400171.3 2014-01-06
GB201400171A GB201400171D0 (en) 2014-01-06 2014-01-06 Dosage regimen
GB201418708A GB201418708D0 (en) 2014-10-21 2014-10-21 Dosage regimen
GB1418708.2 2014-10-21
PCT/IB2015/050098 WO2015101971A1 (en) 2014-01-06 2015-01-06 Dosage regimen of ferric trimaltol

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202111268204.XA Division CN114010629A (zh) 2014-01-06 2015-01-06 三麦芽酚铁的剂量方案

Publications (1)

Publication Number Publication Date
CN106413706A true CN106413706A (zh) 2017-02-15

Family

ID=52432872

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202111268204.XA Pending CN114010629A (zh) 2014-01-06 2015-01-06 三麦芽酚铁的剂量方案
CN201580005412.7A Pending CN106413706A (zh) 2014-01-06 2015-01-06 三麦芽酚铁的剂量方案

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202111268204.XA Pending CN114010629A (zh) 2014-01-06 2015-01-06 三麦芽酚铁的剂量方案

Country Status (12)

Country Link
US (1) US10179120B2 (enExample)
EP (1) EP3091974B1 (enExample)
JP (2) JP6556753B2 (enExample)
KR (1) KR102351422B1 (enExample)
CN (2) CN114010629A (enExample)
AU (1) AU2015204192B2 (enExample)
BR (1) BR112016015766A2 (enExample)
CA (1) CA2934836C (enExample)
ES (1) ES2785391T3 (enExample)
IL (1) IL246613B (enExample)
SI (1) SI3091974T1 (enExample)
WO (1) WO2015101971A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015101971A1 (en) 2014-01-06 2015-07-09 Iron Therapeutics Holdings Ag Dosage regimen of ferric trimaltol
GB201418710D0 (en) 2014-10-21 2014-12-03 Iron Therapeutics Holdings Ag Dosage regimen
AU2017242905B2 (en) 2016-03-31 2020-10-22 Shield TX (UK) Limited Methods for producing ferric maltol compositions from elemental iron
EP3436440B1 (en) 2016-03-31 2020-10-21 Shield TX (UK) Limited Methods for producing ferric maltol compositions from ligand modified and ligand coated ferric hydroxides
EP3435999B1 (en) 2016-03-31 2021-04-28 Shield TX (UK) Limited Ferric maltol compositions for use in the treatment or prevention of cancer and tumours
EP3436442B1 (en) 2016-03-31 2020-10-28 Shield TX (UK) Limited Methods for producing ferric maltol compositions from ferrous hydroxides
GB2553099A (en) * 2016-08-19 2018-02-28 Shield Tx Uk Ltd Use
IT202100018578A1 (it) * 2021-07-14 2023-01-14 Indena Spa Dispersione amorfa di maltolo ferrico e relativo processo di preparazione

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103443091A (zh) * 2011-01-27 2013-12-11 阿文斯若皮帝克斯控股股份公司 方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1150213B (it) * 1982-03-02 1986-12-10 Italfarmaco Spa Derivati di ferro biodisponibile esenti da gastrolesivita',procentimento di preparazione e relative composizioni farmaceutiche
SU1676626A1 (ru) * 1989-05-17 1991-09-15 Тюменский государственный медицинский институт Способ лечени железодефицитных анемий
RO113611B1 (ro) * 1990-08-03 1998-09-30 Asta Pharma Ag Preparate solide de ifosfamida, administrate oral si procedeu de obtinere
WO1996041627A2 (en) 1995-06-10 1996-12-27 Vitra Pharmaceuticals Ltd Iron compounds, compositions, methods of making the same and uses thereof
ID18663A (id) * 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
NZ328751A (en) * 1997-09-16 1999-01-28 Bernard Charles Sherman Solid medicament containing an anionic surfactant and cyclosporin
ES2236300T3 (es) 2000-09-19 2005-07-16 Vitra Pharmaceuticals Ltd. Composiciones de hierro.
US20050118291A1 (en) * 2003-09-10 2005-06-02 Mian-Ying Wang Formulations and methods for treating breast cancer with Morinda citrifolia and methylsulfonymethane
CA2606724A1 (en) * 2005-05-03 2006-11-09 Innozen, Inc. Edible film for transmucosal delivery of nutritional supplements
EP1757299A1 (de) * 2005-08-25 2007-02-28 Vifor (International) Ag Eisen(III)-Komplexverbindungen zur Behandlung von Eisenmangel-Zuständen bei Patienten mit chronisch-entzündlicher Darmerkrankung
US20070111936A1 (en) * 2005-11-15 2007-05-17 Vladimir Pak Complex of alpha-fetoprotein and inducers of apoptosis for the treatment of cancer
GB0808835D0 (en) 2008-05-15 2008-06-18 Vitra Pharmaceuticals Ltd Therapeutic compositions
JP5856725B2 (ja) * 2011-08-02 2016-02-10 和夫 酒井 うつ病治療用または予防用医薬組成物
WO2015101971A1 (en) 2014-01-06 2015-07-09 Iron Therapeutics Holdings Ag Dosage regimen of ferric trimaltol
GB201418710D0 (en) 2014-10-21 2014-12-03 Iron Therapeutics Holdings Ag Dosage regimen

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103443091A (zh) * 2011-01-27 2013-12-11 阿文斯若皮帝克斯控股股份公司 方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DAVID M REFFITT等: "Assessment of iron absorption from ferric trimaltol", 《ANN CLIN BIOCHEM》 *
R. S. J. HARVEY等: "Ferric trimaltol corrects iron deficiency anaemia in patients intolerant of iron", 《ALIMENT PHARMACOL THER》 *

Also Published As

Publication number Publication date
CA2934836C (en) 2022-03-22
EP3091974B1 (en) 2020-04-01
IL246613B (en) 2020-05-31
CA2934836A1 (en) 2015-07-09
JP6556753B2 (ja) 2019-08-07
AU2015204192B2 (en) 2020-03-26
SI3091974T1 (sl) 2020-08-31
CN114010629A (zh) 2022-02-08
ES2785391T3 (es) 2020-10-06
KR20160105499A (ko) 2016-09-06
IL246613A0 (en) 2016-08-31
JP2019131592A (ja) 2019-08-08
WO2015101971A1 (en) 2015-07-09
KR102351422B1 (ko) 2022-01-13
BR112016015766A2 (pt) 2017-08-08
AU2015204192A1 (en) 2016-07-07
EP3091974A1 (en) 2016-11-16
US10179120B2 (en) 2019-01-15
US20160324822A1 (en) 2016-11-10
JP2017501235A (ja) 2017-01-12

Similar Documents

Publication Publication Date Title
AU2015204192B2 (en) Dosage regimen of ferric trimaltol
JP2022070945A (ja) 慢性腎臓病患者の治療におけるクエン酸第二鉄の使用
JP6828100B2 (ja) 慢性腎臓病患者の心不全を軽減するためのクエン酸第二鉄
JP2019510031A (ja) コリン含有の組成物
US11213505B2 (en) Product based on iron bis-glycinate chelate and alginic acid and/or water-soluble salts thereof, formulations thereof, and pharmaceutical uses thereof
CA2965096C (en) Dosage regiment of ferric maltol
AU2015223908B2 (en) Progress-Suppressing or Improving Agent for Chronic Kidney Disease
JPWO2020080499A1 (ja) 新規医薬組成物
WO2019142490A1 (ja) がん患者の治療に有用な尿のアルカリ剤
KR101811376B1 (ko) 경구용 철 결핍증 치료
CN110831587A (zh) 用于预防肥胖症的甜菜碱
IT201700012195A1 (it) Composizione per il trattamento dell'iperuricemia
WO2020222302A1 (ja) 新規医薬組成物
CN105246472B (zh) 含有鸟氨酸和/或门冬氨酸的组合物及其应用
WO2014184435A1 (en) Cysteine or a derivative thereof for the treatment of atrophic gastritis
US20200246414A1 (en) Compositions and methods for the treatment of constipation and other ailments of the gastrointestinal system
WO2020210608A1 (en) Liquid concentrates of calcium and magnesium
KR20060011615A (ko) 생체이용율이 증진된 알렌드론산 제제
NZ724285B2 (en) Agent for improving or preventing progression of chronic kidney disease

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20210423

Address after: Gateshead, UK

Applicant after: British Aegis TX Co.,Ltd.

Address before: Swiss Wollerau

Applicant before: Iron Therapeutics Holdings AG

TA01 Transfer of patent application right
RJ01 Rejection of invention patent application after publication

Application publication date: 20170215

RJ01 Rejection of invention patent application after publication